metastatic colorectal cancer

BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
BioSpace
Fri, 12/8/23 - 10:00 am
Bristol Myers Squibb
Opdivo
Yervoy
colorectal cancer
metastatic colorectal cancer
clinical trials
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
BioSpace
Mon, 08/7/23 - 11:00 pm
Cardiff Oncology
metastatic colorectal cancer
FDA Approves Avastin Biosimilar for Six Types of Cancer
Pharmacy Times
Wed, 09/28/22 - 10:30 pm
FDA
biosimilars
Vegzelma
Avastin
non-small cell lung cancer
glioblastoma
metastatic colorectal cancer
cervical caner
metastatic renal cell carcinoma
Seagen reports positive Phase II tucatinib data in colorectal cancer
Clinical Trials Arena
Tue, 07/5/22 - 11:54 am
Seagen
Tukysa
metastatic colorectal cancer
clinical trials
FDA Approves Pfizer's Braftovi Plus Cetuximab for Colorectal Cancer with BRAF Mutations
BioSpace
Thu, 04/9/20 - 11:34 pm
FDA
Pfizer
Braftovi
Erbitux
metastatic colorectal cancer
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
Yahoo/Zacks.com
Sat, 07/20/19 - 08:25 pm
Bristol-Myers Squibb
Bayer
Ono Pharmaceutical
Opdivo
Stivarga
metastatic colorectal cancer
Bayer, Bristol-Myers Squibb and Ono Pharma Team on Colorectal Cancer
BioSpace
Thu, 07/18/19 - 10:24 am
Bayer
Bristol-Myers Squibb
Ono Pharmaceutical
metastatic colorectal cancer
Opdivo Gains New Approval in Combination with Yervoy
CP Wire
Wed, 07/11/18 - 11:32 am
Opdivo
Yervoy
Bristol-Myers Squibb
metastatic colorectal cancer
Opdivo Gains New Approval in Combination with Yervoy
Wed, 07/11/18 - 10:11 am
Bristol-Myers Squibb
Opdivdo
metastatic colorectal cancer
Early Observations From Aduro Biotech's pLADD Immunotherapy Look Promising
CP Wire
Thu, 04/26/18 - 11:02 am
pLADD
immunotherapy
Aduro BioTech
metastatic colorectal cancer
FDA approves Taiho Oncology's pill for metastatic colorectal cancer
BioPharma Dive
Thu, 09/24/15 - 11:31 am
FDA
metastatic colorectal cancer
Taiho Oncology
Lonsurf
Amgen closed Friday up 4.29% on the back of positive Phase II PEAK results for its mCRC drug, Vectibix
Bidness Etc.
Sat, 01/17/15 - 04:01 pm
Amgen
Vectibix
metastatic colorectal cancer
mCRC